1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
10qk
10qk
Articles 

Immunomedics Inc. Reports Operating Results (10-Q)

February 08, 2013 | About:

Immunomedics Inc. (NASDAQ:IMMU) filed Quarterly Report for the period ended 2012-12-31.

Immunomedics, Inc. has a market cap of $222.558 million; its shares were traded at around $2.93 with and P/S ratio of 58.8235.

Highlight of Business Operations:

Revenues for the three-month period ended December 31, 2012 were $0.8 million, as compared to $29.7 million for the same period in 2011, representing a decrease of $28.9 million or 97%. The decrease was due to $28.4 million of license fee revenue earned in the three-month period ended December 31, 2011 under the terms of the Amendment Agreement with UCB. There was no similar license fee revenue earned during the three-month period December 31, 2012. Product sales for the three-month period ended December 31, 2012 were $0.7 million, as compared to $1.1 million for the same period in 2011, representing a decrease of $0.4 million or

Total costs and expenses for the three-month period ended December 31, 2012 were $8.6 million, as compared to $8.5 million for the same period in 2011, representing an increase of $0.1 million or 1%. Research and development expenses for the three-month period ended December 31, 2012 were $6.7 million as compared to $6.4 million for the same period in 2011, an increase of $0.3 million or 5%. The increase in research and development expenses resulted primarily from an increase of $0.8 million of clinical trial related expenses partially offset by the deferral of manufacturing expenses incurred for inventory production in 2012. Cost of goods sold for the three-month periods ended December 31, 2012 and 2011 was $0.1 million for both periods with gross profit margins at 87%, for both periods. General and administrative costs were $1.7 million for both the three-month periods ended December 31, 2012 and 2011, respectively.

Net loss for the three-month period ended December 31, 2012 was $5.4 million, or $0.07 per basic share, as compared to net income of $20.7 million, or $0.27 per basic share, for the same period in 2011 representing a decrease of $26.1 million. The decrease in net income reported in fiscal 2013 as compared to fiscal 2012 resulted primarily from the decrease of $28.4 million of license fee revenues recorded from the Amendment Agreement entered into with UCB during the second quarter of fiscal 2012, partially offset by $2.5 million of insurance proceeds received in fiscal 2013.

or 94%. The decrease was primarily due to $28.4 million of license fee revenue earned in the previous year under the terms of the Amendment Agreement with UCB. Product sales for the six-month periods ended December 31, 2012 and 2011 were $1.5 million and $1.9 million, respectively, representing a decrease of $0.4 million or 21% as sales volume of LeukoScan in Europe have declined from the prior year primarily as a result of regulatory delays that we are working to resolve . Research and development revenues for the six-month period ended December 31, 2012 were $0.4 million as compared to $0.5 million for the previous year, a decrease of $0.1 million or 20% due to the timing of program spending and the number of grant programs in place during each period.

Total costs and expenses for the six-month period ended December 31, 2012 were $17.3 million, as compared to $14.8 million for the same period in 2011, representing an increase of $2.5 million or 17%. Research and development expenses for the six-month period ended December 31, 2012 were $13.7 million as compared to $11.2 million for the same period in 2011, an increase of $2.5 million or 22%. The increase in research and development expenses resulted primarily from $1.6 million of lower expense reimbursements than received in the prior year, and $0.9 million of increased clinical trial activities. Cost of goods sold for each of the six-month periods ended December 31, 2012 and 2011 was $0.2 million. Gross profit margins were 87% and 88%, respectively, for the first six months of fiscal 2013 and fiscal 2012. General and administrative costs were $3.0 million for the six-month period ended December 31, 2012, and $2.9 million for the same period in 2011, an increase of $0.1 million or 3%.

Read the The complete Report

About the author:

10qk
GuruFocus - Stock Picks and Market Insight of Gurus

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Select portfolio(s):

  • Loading...

Why you are interested?

Your selection and notes will be stored in your portfolio.

Login to add portfolio
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK